Antibiotic resistances and eradication rates in Helicobacter pylori infection

Arcos, Gonzalo Botija; Rodríguez, Clara García; Linares, Aránzazu Recio; Gutiérrez, Carolina Campelo; Pérez‐Fernández, Elia; Merino, Alfonso Barrio

doi:10.1016/j.anpede.2020.10.010

Cited by 9 publications

(19 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Among the tested antibiotics, the highest resistance rates were for clarithromycin and metronidazole. This finding correlates with previous studies that also reported on these two antibiotics associated with the most prevalent resistance rates, compared with other antibiotics 2,14,15 …”

Section: Discussionsupporting

confidence: 92%

“…Along with the increasing resistance rates to each antibiotic, the rates of multi‐resistance also increased during the study period. This phenomenon is also common in other geographic areas and elucidates the decreasing rates of eradication success 1,15,16 . According to a recent report by the European Centre for Disease Prevention and Control regrading antimicrobial consumption in 27 European Union (EU) Member States and two European Economic Area (EEA) countries (Iceland and Norway), overall antibiotic consumption has been decreased during 2011–2020.…”

Section: Discussionmentioning

confidence: 97%

“…This finding correlates with previous studies that also reported on these two antibiotics associated with the most prevalent resistance rates, compared with other antibiotics. 2,14,15 Throughout the surveillance period, resistance rates to most antibiotics increased. Similar to our results, a previous study from Italy demonstrated an increased trend in resistance rates to clarithromycin and levofloxacin from 2009-2014 to 2015-2019.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Antibiotic resistance patterns of Helicobacter pylori in North Israel – A six‐year study

Azrad

Vazana

et al. 2022

Helicobacter

View full text Add to dashboard Cite

Background: One main challenge in Helicobacter pylori (H. pylori) eradication is its increasing antibiotic resistance. Additionally, resistance rates vary between geographic areas and periods. However, data are limited since susceptibility testing is not routinely performed. Thus, it is valuable to gather data regarding H. pylori's resistance rates in Israel that would aid in better adjustment of treatment.

show abstract

Section: Discussionsupporting

confidence: 92%

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Antibiotic resistance patterns of Helicobacter pylori in North Israel – A six‐year study

Azrad

Vazana

et al. 2022

Helicobacter

View full text Add to dashboard Cite

show abstract

“…The MDR rate (6.6%) in Bulgarian children determined according to the EUCAST breakpoints was higher than those in other studies also based on EUCAST breakpoints such as those in Slovenia in 2011-2014 (3.8%), Lithuania in 2013-2015 (0%) and Spain in 2014-2019 (0%), [11,14,17]. The MDR prevalence in our study was much lower than those (20.7% in the untreated and 47.0% in the treated children) in China in 2019, which were also detected by EUCAST breakpoints with the exception of the breakpoint for amoxicillin resistance (>0.25 mg l À1 ), [18].…”

Section: Discussioncontrasting

confidence: 59%

“…MDR rates in H. pylori in pediatrics have widely varied from 0 to >41% [10][11][12][13][14][15][16][17][18] (Table 3). However, the comparison of the results is difficult since different breakpoints for resistance were used in different studies (Table 3).…”

Section: Discussionmentioning

confidence: 99%

Investigation of multidrug-resistant Helicobacter pylori in pediatric patients: A Bulgarian study and literature data

Boyanova

Hadzhiyski

Markovska

et al. 2022

AMicr

View full text Add to dashboard Cite

Antibiotic resistance of Helicobacter pylori strains from 106 symptomatic children was evaluated according to EUCAST breakpoints and rate of multidrug resistance (MDR) was analyzed. Overall resistance rates were amoxicillin 7.5%, metronidazole 25.5%, clarithromycin 34.0% and ciprofloxacin 14.1%. There were no significant differences in resistance rates according to patients' age (2–6 and 7–18 years) and sex. Combined resistance rate was 19.8%, including double, triple, and quadruple resistance in 13.2% (14 strains), 5.7% (6) and 0.9% (1) of the strains, respectively. MDR was found in 5.9% (5/84) of the children with gastritis and in two of the four children with celiac disease. The MDR was present in three children aged 4–6 years and in four children aged 10–17 years. The total MDR rate (6.6%) in Bulgarian children in 2012–2021 was higher than those in other studies based on EUCAST breakpoints such as those in pediatric patients in Slovenia in 2011–2014 (3.8%), Lithuania in 2013–2015 (0%) and Spain in 2014–2019 (0%), although being lower than those (20.7% in the untreated and 47.0% in the treated children) in China in 2019. In brief, it is of concern that MDR can strongly limit the choice of H. pylori therapy of one out of fifteen Bulgarian children and that overall resistance to both metronidazole and clarithromycin can hinder the treatment of 15.1% of the pediatric patients. Susceptibility-guided tailored eradication therapy of H. pylori infection should be more frequently implemented in the symptomatic children to avoid risks of both the infection itself and multiple antibiotic treatments.

show abstract

Effects of probiotics on gastric microbiota and its precombination with quadruple regimen for Helicobacter pylori eradication

You

Dong

Zhou

et al. 2022

J of Digest Diseases

View full text Add to dashboard Cite

Objectives: This study aimed to assess the efficacy and safety of probiotics for Helicobacter pylori (H. pylori) eradication therapy as well as their effects on gastric microbiota.Methods: Patients who had failed H. pylori eradication therapy for at least twice were prospectively enrolled during March 2019 and March 2021. A 2-week administration of compound Lactobacillus acidophilus probiotic (1 g thrice daily) followed by a 10-day quadruple bismuth-containing H. pylori eradication therapy was administrated. Endoscopy was performed, and gastric biopsy samples were obtained for drug sensitivity testing and 16S rRNA gene sequencing before and after probiotic treatment. Eradication was evaluated by the 13 C-urea breath test at least 4 weeks after treatment completion. Adverse events (AEs) were recorded.Results: Thirty-seven patients were included. Probiotic supplementation had no effects on the diversity, community structure, and composition of gastric microbiota and no inhibition on H. pylori activity. However, it increased some of the beneficial bacteria such as Blautia, Dorea, and Roseburia (P < 0.05). The overall eradication rate was 97.3% (95% confidence interval [CI] 91.8%-100%). AEs, mainly dizziness, nausea, diarrhea, and chest distress, were detected in six individuals, all of which were resolved upon cessation of antibiotic administration. Dyspeptic symptoms were improved after probiotic supplementation and at treatment completion (both P < 0.001).Conclusions: H. pylori-infected individuals might benefit from probiotics followed by a quadruple bismuth-containing eradication therapy. Further studies with large sample sizes are warranted.

show abstract

Antibiotic resistances and eradication rates in Helicobacter pylori infection

Cited by 9 publications

References 24 publications

Antibiotic resistance patterns of Helicobacter pylori in North Israel – A six‐year study

Antibiotic resistance patterns of Helicobacter pylori in North Israel – A six‐year study

Investigation of multidrug-resistant Helicobacter pylori in pediatric patients: A Bulgarian study and literature data

Effects of probiotics on gastric microbiota and its precombination with quadruple regimen for Helicobacter pylori eradication

Contact Info

Product

Resources

About